LSD Analogues for Health & Longevity
Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: LSD Analogs, LSD Derivatives, LSD Congeners, Lysergic Acid Diethylamide Analogues, Lysergamide Analogues, Novel Lysergamides, Lysergamides, Substituted Lysergamides, 1P-LSD, 1cP-LSD, ALD-52, AL-LAD, ETH-LAD, LSZ, 2-Br-LSD, BOL-148
Motivation
LSD analogues are close chemical relatives of lysergic acid diethylamide (LSD), the best-known psychedelic compound. Examples include 1-propionyl-LSD (1P-LSD) and 6-ethyl-nor-LSD (ETH-LAD), which are sold online as research chemicals. Some are converted into LSD inside the body, while others act on their own. They draw interest from health- and longevity-oriented adults who follow LSD research on mood and anxiety.
LSD was first made in 1938, and altered versions have been studied for decades. After LSD became a controlled substance, new variants appeared from 2013 onward, often marketed as legal alternatives. Meanwhile, clinical trials have tested LSD itself for anxiety, and a chemically modified relative intended to avoid hallucinations has been examined in animals and in a small clinical study.
This review examines what human and laboratory evidence exists for LSD analogues in the context of health and longevity, how their effects and risks relate to those of LSD, and what is known about product identity, quality, and legal status. It also considers how far the LSD literature can be carried over to analogues.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Expert commentary and primary research that discuss LSD analogues or the serotonin pathway they share with LSD.
-
Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health - Andrew Huberman
Explains how LSD and related psychedelics act through the serotonin 2A receptor (5-HT2A, a brain receptor that psychedelics activate), with a segment on low-dose LSD and a nonhallucinogenic-analogue paper.
-
Psychedelic Drugs for Alzheimer’s Treatment - Josh Conway
Summarises a review tying psychedelic activation of 5-HT2A to brain plasticity in age-related nerve-cell loss such as Alzheimer’s disease, giving longevity-relevant context for LSD-type compounds.
-
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD) - Halberstadt et al., 2020
ALD-52, 1P-LSD and 1B-LSD bind serotonin receptors weakly in cells, yet rats rapidly converted ALD-52 and 1P-LSD to LSD, a prodrug (compound activated in the body) pattern; co-authors include Synex Synthetics staff.
-
Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists? - Kehler & Lindskov, 2025
Narrative review finding no basis for calling lisuride or ergotamine non-hallucinogenic at brain-relevant concentrations, and cautioning that animal data alone cannot establish this for any compound activating 5-HT2A.
-
Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration - Grumann et al., 2020
Pharmacokinetic (body-handling) study: two volunteers received 100 µg 1P-LSD orally or intravenously; oral administration produced only LSD in blood, with near-complete conversion and LSD-like effects. Only two participants; co-authors include Synex Synthetics staff.
No relevant content on LSD analogues was found from Rhonda Patrick (FoundMyFitness material centres on psilocybin, with LSD appearing only as one drug in broader summaries), Peter Attia (psychedelic episodes and articles centre on psilocybin, 3,4-methylenedioxymethamphetamine (MDMA, a psychoactive drug that heightens feelings of empathy), and drug policy), Chris Kresser (a psychedelic-assisted psychotherapy episode centred on MDMA), or Life Extension Magazine (only brief psychedelic passages within condition protocols).
Grokipedia
Class-level article on lysergamide chemistry, 5-HT2A pharmacology and history, briefly naming analogues such as 1P-LSD, LSZ and ETH-LAD; separate pages exist for individual compounds.
Examine
Examine has no page on LSD analogues; this page covers the parent compound and summarises preliminary evidence for psychiatric use. Detailed study summaries sit behind a paid membership.
ConsumerLab
ConsumerLab has no article on LSD analogues or LSD. ConsumerLab does not typically review controlled or unapproved psychoactive research chemicals.
Systematic Reviews
Systematic reviews (structured literature searches) and meta-analyses (pooled statistical analyses of several studies) retrieved from PubMed, each labelled with the compound it covers.
-
Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials - Castro et al., 2025
Seventeen human studies of lysergic acid amide (LSA) report hallucinations, loss of contact with reality and high blood pressure; covers LSA alone, not synthetic analogues.
No systematic review or meta-analysis of the substituted lysergamides (1P-LSD, 1cP-LSD, ALD-52, AL-LAD, ETH-LAD) was found on PubMed as of 09/30/2026. The only systematic review of a lysergamide concerns lysergic acid amide, so the effect and risk of the substituted analogues themselves are unrepresented.
Mechanism of Action
LSD analogues are lysergamides: compounds built on lysergic acid, the ergot-derived (grain fungus) core of LSD. LSD is not selective: its psychedelic effects depend mainly on 5-HT2A, but it also acts on 5-HT1A (serotonin 1A receptor) and dopamine receptors, and it enters the brain. Oral LSD has a plasma half-life (time for the concentration to halve) of 2.6–3.6 hours (Dolder et al., 2017; Dolder et al., 2015).
N1-acyl analogues (ALD-52, 1P-LSD, 1cP-LSD, 1B-LSD) carry an acyl group (a short carbon chain) on the indole nitrogen; they bind serotonin receptors weakly, yet rats convert them rapidly to LSD (Halberstadt et al., 2020; Berquist et al., 2026). In two volunteers, oral 1P-LSD yielded only LSD in blood with near-complete bioavailability (fraction reaching the bloodstream) (Grumann et al., 2020). LSZ acts directly, unconverted (Berquist et al., 2026); AL-LAD and ETH-LAD, lacking an acyl group, are presumed directly active, and AL-LAD produced LSD-like mouse behaviour (Brandt et al., 2017; Synex-affiliated co-author).
Liver enzymes CYP1A2 and CYP3A4 (which break down many drugs) modify these compounds (Wagmann et al., 2019; Synex-affiliated co-author); CYP2D6 (another such enzyme) also clears LSD (Becker et al., 2025).
Competing accounts: benefit requires hallucinogenic 5-HT2A activation, or plasticity separates from hallucinations. 2-Br-LSD did not trigger the head-twitch response (a mouse behaviour tracking 5-HT2A activation) and lacked 5-HT2B (serotonin 2B receptor) activation, which is linked to heart-valve damage (Lewis et al., 2023; BetterLife Pharma co-authors), yet a review found no basis for calling lisuride or ergotamine non-hallucinogenic (Kehler & Lindskov, 2025).
Historical Context & Evolution
Lysergic acid derivatives were first studied by pharmaceutical chemists working on ergot alkaloids; LSD itself was synthesised in 1938 by Albert Hofmann. Chemists later made modified versions to map how structure shapes activity and to seek therapeutics: ALD-52 dates to the 1950s, and AL-LAD and related compounds were characterised in academic work (Brandt et al., 2016; Brandt et al., 2017; Synex-affiliated co-authors). The bromine-substituted BOL-148 (2-Br-LSD) was also studied in the 1950s; one report described LSD-like delirium (acute confusion with hallucinations) after a small amount (Richards et al., 1958), and its hallucinogenicity was still questioned in 2011 (Tfelt-Hansen, 2011).
After LSD was scheduled worldwide, clinical work such as its analgesic (pain-relieving) research evaporated (Ramaekers et al., 2021). Lysergamides then reappeared as unscheduled research chemicals: AL-LAD and LSZ in 2013, 1P-LSD in 2015, then 1cP-LSD, often marketed as legal alternatives to LSD (Grumann et al., 2020; Brandt et al., 2020; Synex-affiliated co-authors). The first characterisation of 1P-LSD found LSD-like head-twitch responses in mice at about 38% of LSD’s potency (Brandt et al., 2016).
Interest in health optimisation followed LSD’s clinical revival, the spread of microdosing (repeated doses too low to cause obvious perceptual effects), and laboratory signals of plasticity and lifespan extension in animals. Opinion has shifted over time: the view that acyl analogues simply behave as LSD rests on rodent data and two human volunteers, and the non-hallucinogenic label for some analogues has been challenged (Kehler & Lindskov, 2025).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: replicated controlled human trials exist only for LSD itself, and none has tested an analogue on a health outcome.
Medium 🟩 🟩
No benefit reaches Medium: for analogues, human data are limited to a two-volunteer pharmacokinetic study and self-reported surveys, which describe use patterns rather than health outcomes.
Low 🟩
Anxiety symptom reduction (LSD-derived)
Indirect: LSD, not an analogue, lowered anxiety in placebo-controlled trials, including one in generalized anxiety disorder (GAD, persistent excessive worry) (Robison et al., 2025) that was sponsor-run by developer MindMed (now Definium Therapeutics) with employee authors. Analogues converting to LSD could deliver this, but no analogue trial exists.
Magnitude: LSD 100 µg lowered the Hamilton Anxiety Rating Scale (HAM-A, a clinician-rated anxiety score) by 5.0 points versus placebo at week 4, and 200 µg by 6.0 points (Robison et al., 2025); a smaller trial in anxiety with or without life-threatening illness found a State-Trait Anxiety Inventory difference of 16.2 points at 16 weeks (Holze et al., 2023).
Depressive symptom reduction (LSD-derived) ⚠️ Conflicted
Indirect: in one randomised trial of LSD-assisted therapy for major depression, clinician-rated symptoms improved more with high than low doses, yet the self-rated primary measure missed significance (Müller et al., 2025). Net reading: benefit possible but unproven, and untested for analogues.
Magnitude: The Inventory of Depressive Symptomatology (a depression symptom score) fell 12.9 points with high-dose versus 3.6 with low-dose LSD (difference −9.2; 95% confidence interval, CI, the range likely containing the true value, −17.1 to −1.3); the self-rated difference was −7.9 (CI −16.0 to 0.3) (Müller et al., 2025).
Pain tolerance from low-dose LSD ⚠️ Conflicted
Indirect: in healthy volunteers, single 20 µg LSD doses lengthened cold-water tolerance (Ramaekers et al., 2021), but four 15 µg doses showed no analgesic effect (Cavarra et al., 2025). Both tested LSD alone. Net reading: unresolved and possibly dose-dependent, with no analogue data.
Magnitude: In the 20 µg trial, treatment explained about 9% of the variance in cold-water tolerance (partial eta-squared, a variance-explained effect size, 0.09) (Ramaekers et al., 2021); the 15 µg trial found no effect on any pain measure (Cavarra et al., 2025).
Mood and cognition in healthy adults from low-dose LSD ⚠️ Conflicted
Indirect: single 20 µg LSD doses raised positive mood and reduced attentional lapses but also increased anxiety and confusion (Hutten et al., 2020), whereas four repeated low doses changed mood and cognition negligibly (de Wit et al., 2022). Net reading: small, inconsistent effects, untested for analogues.
Magnitude: Direction depends on dose and schedule: positive mood rose at 20 µg and attentional lapses fell at 5 and 20 µg after single doses, whereas four doses of 13 or 26 µg improved neither mood nor most performance measures; the literature reports no pooled outcome figure.
Sleep duration after low-dose LSD
Indirect: in a trial of 80 healthy men, LSD 10 µg every third day for six weeks lengthened sleep on the night after dosing, with no loss of sleep on dosing days (Allen et al., 2024). It tested LSD alone, in men only, and no analogue has been examined.
Magnitude: Participants slept an extra 24.3 minutes on the night after microdosing versus placebo (95% CI 10.3–38.3 minutes) (Allen et al., 2024).
Cluster headache attack prevention (2-Br-LSD) ⭕️ Not Central to Health & Longevity
In a small, open, uncontrolled case series of cluster headache (severe one-sided headache attacks), three doses of 2-Br-LSD reportedly broke or reduced attack cycles (Karst et al., 2010). It bears on headache treatment, not healthy adults’ longevity, and BOL-148’s hallucinogenicity is disputed.
Magnitude: Direction only: fewer attacks after three oral doses in a small open-label series; the literature reports no controlled outcome figure (Karst et al., 2010).
Alcohol misuse reduction (LSD-derived) ⭕️ Not Central to Health & Longevity
Indirect: a meta-analysis of six randomised trials in alcoholism found that a single LSD dose, given within treatment programmes, was associated with less alcohol misuse (Krebs & Johansen, 2012). The trials tested LSD alone, and no analogue has been examined. It bears on alcoholism treatment, not healthy adults’ longevity.
Magnitude: Alcohol misuse decreased more with LSD than with control: odds ratio (OR, the odds of a favourable outcome relative to control) 1.96 (95% CI 1.36–2.84; six trials, 536 participants) (Krebs & Johansen, 2012).
Speculative 🟨
Structural neuronal plasticity
Cell and rodent studies show LSD-type psychedelics increase neuronal branching and synapse number via 5-HT2A and growth pathways such as mTOR (a cell-growth pathway) (Ly et al., 2018). Mechanistic evidence only; no human data.
Reduced neuroinflammation
Reviews describe 5-HT2A activation dampening inflammatory signalling in microglia (brain immune cells) and cytokine (immune messenger) release (de Deus et al., 2025). Evidence is preclinical and mechanistic; no analogue or human outcome data.
Lifespan extension
LSD lengthened lifespan in the roundworm Caenorhabditis elegans in a preprint (not yet peer reviewed) (Carrilho et al., 2025); psilocybin extended survival in aged mice (Kato et al., 2025). No analogue or human data.
Lower hallucinogenic and heart-valve liability in engineered analogues
2-Br-LSD lacked 5-HT2B activation and reversed stress effects in mice (Lewis et al., 2023; BetterLife Pharma co-authors), and simplified LSD-core compounds (ergolines) showed reduced heart-damage potential (Basargin et al., 2026). Cell and animal data only.
Benefit-Modifying Factors
- Genetics: CYP2D6 status changes LSD exposure, as paroxetine raised it 1.5-fold most in normal metabolisers (Becker et al., 2025); no genetic variant has been linked to response to analogues.
- Baseline biomarkers: The generalized anxiety trial enrolled moderate to severe anxiety (Hamilton score of 20 or more) (Robison et al., 2025); depressed mood amplified subjective effects of low-dose LSD (Molla et al., 2024). No biomarker predicts benefit from analogues.
- Sex: LSD pharmacokinetics did not differ between 8 men and 8 women (Dolder et al., 2015); sex-specific benefit has not been reported for analogues.
- Pre-existing conditions: Benefit signals come from anxiety, depression and cluster headache; in healthy adults LSD mainly produces acute, dose-dependent effects (Holze et al., 2022). No analogue data exist.
- Age: Older volunteers (mean age 62.9 years) tolerated low-dose LSD in a trial by the developer Eleusis (Family et al., 2020); the anxiety trial enrolled ages 18 to 74 (Robison et al., 2025). Efficacy in older adults is untested.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: replicated controlled human trials of adverse events exist only for LSD itself, and none has studied an analogue.
Medium 🟥 🟥
Acute psychedelic effects and challenging experiences
Analogues produce LSD-like perceptual changes lasting about 8 hours, presumably through 5-HT2A activation after conversion to LSD or direct action. Users of AL-LAD, 1P-LSD and ETH-LAD rated the effects psychedelic in 93% of reports (Coney et al., 2017), and two volunteers showed LSD-like effects from 1P-LSD (Grumann et al., 2020). Anxiety, nausea and headache are documented in LSD trials, not measured for analogues, and analogue doses remain unverified.
Magnitude: In LSD trials, visual perceptual changes occurred in 92.5% at 100 µg versus 10.3% with placebo, nausea in 40.0% and headache in 35.0% (Robison et al., 2025); analogue-specific incidence is not available.
Low 🟥
Severe toxicity from unverified analogues
An adolescent developed aggression, unconsciousness, injuries and metabolic disturbances after analytically confirmed ETH-LAD ingestion (Nadler et al., 2026), and a fatal ventricular dysrhythmia (dangerous heart rhythm) was reported with AL-LAD (Blumenberg & Hendrickson, 2020). These are uncontrolled case reports; causality and doses are uncertain.
Magnitude: Not quantified in available studies. Only single case reports exist, so no incidence can be estimated.
Persistent perceptual and psychotic symptoms
Transient flashbacks occurred in 6 of 83 healthy participants after LSD (Holze et al., 2022), while trials reported no persistent psychosis (loss of contact with reality) or hallucinogen persisting perception disorder (HPPD, lasting visual disturbances) (Hinkle et al., 2024). One ETH-LAD case ended in persistent psychosis.
Magnitude: Six of 83 participants (7%) reported transient flashbacks after LSD (Holze et al., 2022); no cases of persistent psychosis or HPPD appeared in contemporary trials of classic psychedelics (Hinkle et al., 2024); analogue rates are unknown.
Acute blood pressure, heart-rate and temperature elevation
LSD raises blood pressure, heart rate and body temperature dose-dependently in controlled trials (Holze et al., 2022). Trial data come from LSD, so applicability to analogues is indirect.
Magnitude: In pooled LSD trials, peak heart rate exceeded 100 beats per minute in 20% of participants at 100 µg and 25% at 200 µg, body temperature exceeded 38°C in 34% at 200 µg, and systolic blood pressure never exceeded 180 mmHg (Holze et al., 2022).
Seizures, mainly with lithium
Seizure reports cluster with lithium co-use: online experience reports (Nayak et al., 2021) and one adolescent case (Edwards et al., 2024). Evidence is uncontrolled and LSD-based.
Magnitude: Among 62 online reports of lithium co-administered with a classic psychedelic, 47% described seizures; these are self-selected reports, not an incidence (Nayak et al., 2021).
Speculative 🟨
Heart-valve damage from repeated exposure
LSD and likely analogues activate 5-HT2B, linked to valve scarring with ergot-type drugs such as pergolide (Rouaud et al., 2024). No study has tested valve outcomes with psychedelics (Tagen et al., 2023); risk is inferred.
Unknown organ toxicity
Computer models predict genotoxicity (DNA damage) alerts and heart-rhythm channel inhibition for N1-acyl analogues (Jurowski et al., 2026); 1cP-LSD caused no cytotoxicity (cell damage) in liver cells (Gampfer et al., 2024). Predictive or cell data.
Product misidentification, impurities and dose uncertainty
Forensic laboratories found unlisted analogues in paper-sheet products (Tanaka et al., 2025), and a commercial 1cP-AL-LAD sample contained 17 impurities (Kavanagh et al., 2023; Synex Synthetics co-authors). Evidence is analytical only, without human outcome data.
Risk-Modifying Factors
- Genetics: CYP2D6 inhibition by paroxetine raised LSD exposure 1.5-fold, most in normal metabolisers (Becker et al., 2025); genetic effects on analogue toxicity are untested.
- Baseline biomarkers: Higher resting blood pressure and heart rate, or a long QTc (QT interval corrected for heart rate, an electrical-recovery measure on an electrocardiogram), would add cardiovascular strain; a Basel trial excludes blood pressure above 140/90 mmHg (NCT07309471).
- Sex: No sex differences appeared in LSD pharmacokinetics (Dolder et al., 2015); sex-specific adverse-event data for analogues are absent.
- Pre-existing conditions: The same trial excludes psychotic or bipolar disorder (recurring swings between mania and depression) in the participant or a first-degree relative (NCT07309471); depressed mood amplified subjective effects of low-dose LSD (Molla et al., 2024).
- Age: Older volunteers tolerated low-dose LSD with adverse events no higher than placebo (Family et al., 2020); the ETH-LAD case involved an adolescent.
Key Interactions & Contraindications
- Selective serotonin reuptake inhibitors, SSRIs (paroxetine, fluoxetine, sertraline; a common antidepressant class): Monitor. Paroxetine cut LSD-induced anxiety and nausea but raised LSD exposure 1.5-fold via CYP2D6 inhibition; no dose adjustment was judged necessary (Becker et al., 2025). Other SSRIs are untested.
- Lithium: Serious caution; consequence: seizures. Online reports link psychedelic-lithium co-use to seizures (Nayak et al., 2021), and an adolescent on low-dose lithium had new-onset seizures after LSD (Edwards et al., 2024).
- 5-HT2A blockers and antipsychotics (ketanserin, olanzapine, risperidone; medications blocking the receptor LSD acts on): Monitor; consequence: loss of effect. Ketanserin blocked LSD’s subjective effects in a controlled study (Preller et al., 2017); others presumed similar. A Basel trial tested olanzapine after LSD (NCT05964647).
- CYP inhibitors and inducers (bupropion, ketoconazole, rifampicin; drugs that slow or speed enzyme activity): Monitor; altered exposure or duration. Analogues are cleared by CYP1A2 and CYP3A4 (Wagmann et al., 2019), and CYP2D6 also clears LSD; effects of these specific drugs are untested.
- Serotonergic prescription drugs (sumatriptan, tramadol, phenelzine; medications that raise serotonin activity): Caution, theoretical. Additive serotonin effects could cause serotonin syndrome (agitation, fever, muscle rigidity); no LSD-specific data. Phenelzine is a monoamine oxidase inhibitor (an older antidepressant class).
- Over-the-counter decongestants (pseudoephedrine, phenylephrine): Monitor; additive blood-pressure and heart-rate rise, as LSD raises both (Holze et al., 2022). Dextromethorphan (a cough suppressant) is serotonergic; no direct data.
- Serotonergic supplements (5-hydroxytryptophan, St John’s wort, S-adenosylmethionine; serotonin-raising): Caution, theoretical; additive serotonin effects and possible serotonin syndrome. No LSD-analogue interaction study exists.
- Caffeine and other stimulants (guarana, yohimbine): Monitor; additive heart-rate and anxiety effects. A Basel trial requires abstaining from caffeine-type drinks on session days (NCT07309471).
- Alcohol, cannabis and other psychedelics (psilocybin, mescaline): Caution; expected additive impairment and anxiety; no analogue data. Trials require abstinence from illicit psychoactive substances.
Populations who should avoid LSD Analogues:
- Personal or first-degree family history of psychotic or bipolar disorder: excluded from trials because of psychosis risk (NCT07309471).
- Uncontrolled hypertension (above 140/90 mmHg) or low blood pressure (systolic below 85 mmHg): excluded from the same trial.
- Long QT syndrome (a heart-rhythm disorder; QTc above 450 ms in men or 460 ms in women), known arrhythmia, or heart-valve disease: inferred from the AL-LAD fatality and 5-HT2B risk.
- Seizure disorder or current lithium therapy: seizure reports with lithium.
- Pregnancy and breastfeeding: excluded from trials; no analogue safety data.
- Adolescents: the ETH-LAD toxicity case involved an adolescent.
Risk Mitigation Strategies
- Laboratory identity confirmation: Mass-spectrometry testing of the specific batch addresses misidentified products, such as unlisted analogues found in paper-sheet products (Tanaka et al., 2025); colour reagents flag only an indole and cannot tell lysergamides apart.
- Psychiatric history screening: Trials exclude psychotic or bipolar history in the participant or first-degree relatives, mitigating psychosis and persistent perceptual symptoms (NCT07309471).
- Cardiovascular pre-screening: Blood pressure below 140/90 mmHg and a normal electrocardiogram with QTc check address hypertensive spikes and arrhythmia, given the fatal AL-LAD report (Blumenberg & Hendrickson, 2020).
- Low-dose schedules: Negative-effect ratings above 50% occurred in 0% of administrations at 25 µg versus 31% at 200 µg, lowering acute distress risk (Holze et al., 2022).
- Supervised setting: Trial sessions last about 13 hours with monitoring (NCT07309471), mitigating challenging experiences and injuries like those in the ETH-LAD case.
- Spaced repeated dosing: Doses spaced four days apart across six administrations (Family et al., 2020) limit cumulative 5-HT2B exposure and tolerance; valve imaging is proposed for long-term users (Rouaud et al., 2024).
- Medication review: Excluding lithium and reviewing SSRI use addresses seizure and altered-exposure risks (Nayak et al., 2021).
- Activity restriction: A Basel trial bars operating heavy machinery for 48 hours after dosing, addressing impaired-judgement accidents (NCT07309471).
Therapeutic Protocol
- Clinical (trial) protocol: Supervised sessions with LSD at 25–200 µg; the generalized anxiety trial tested single doses across that range (Robison et al., 2025), the depression trial two sessions with psychotherapy (Müller et al., 2025).
- Analogue use patterns: No clinical protocol exists. Self-administered 100 µg 1P-LSD produced LSD-like effects in two volunteers (Grumann et al., 2020); survey users report variable doses and durations (Mallaroni et al., 2022).
- Low-dose schedules: Trials used 5, 10 or 20 µg every fourth day for six doses (Family et al., 2020) or 10 µg every third day for six weeks (Allen et al., 2024).
- Competing approaches: Supervised full-dose sessions, repeated sub-perceptual doses and unsupervised self-administration coexist; none is established as default for analogues. Basel (Liechti, Müller), Maastricht (Ramaekers) and the sponsor Definium Therapeutics are associated with the first two.
- Time of day: Effects last 8–12 hours (Dolder et al., 2017) and Basel sessions run about 13 hours (NCT07309471), so morning starts leave the effect window clear of sleep; low doses lengthened next-night sleep.
- Half-life: LSD plasma half-life is 2.6–3.6 hours (Dolder et al., 2015); LSD released from 1P-LSD showed 5.7–6.4 hours in two volunteers (Grumann et al., 2020).
- Single versus split doses: LSD trials use one oral dose per session; split dosing within sessions is untested. Low-dose regimens separate doses by three to four days.
- Genetics: CYP2D6 inhibition raised LSD exposure 1.4–1.5-fold, most in normal metabolisers (Becker et al., 2025).
- Sex: LSD pharmacokinetics showed no sex differences (Dolder et al., 2015); response differences are unreported for analogues.
- Age: Older volunteers tolerated 5–20 µg LSD (Family et al., 2020); anxiety trial participants were aged 18–74 (Robison et al., 2025).
- Baseline biomarkers: Baseline blood pressure and heart rate determine trial eligibility; baseline anxiety of 20 or more Hamilton points defined the anxiety trial population (Robison et al., 2025).
- Pre-existing conditions: Psychotic or bipolar history and interacting medications exclude participants, and depressed mood amplified low-dose effects (Molla et al., 2024).
Discontinuation & Cycling
- Duration: Use is episodic rather than lifelong: clinical LSD protocols involve one or two sessions (Robison et al., 2025; Müller et al., 2025). No analogue protocol defines duration.
- Withdrawal effects: None are described in the LSD trials reviewed here, and no analogue data exist; flashbacks after exposure are the recorded aftereffect (Holze et al., 2022).
- Tapering: Not applicable for episodic use; low-dose schedules simply stop after a fixed number of doses (Family et al., 2020).
- Cycling: Tolerance (weaker response after repeated exposure) carries over between 5-HT2A-activating compounds in mice (de la Fuente Revenga et al., 2022), and trials space doses three to four days apart; 2-Br-LSD induced no tolerance (Lewis et al., 2023).
Sourcing and Quality
- No regulated supply: No analogue is approved; pharmaceutical-grade LSD exists only in investigational forms, such as Definium Therapeutics’ orally disintegrating tablet. Analogues are sold online as research chemicals, and one tested 1cP-AL-LAD sample came from an online vendor (Kavanagh et al., 2023).
- Identity and purity: Laboratories detected unlisted analogues in paper-sheet products (Tanaka et al., 2025) and 17 impurities in one powder (Kavanagh et al., 2023).
- Analytical pitfalls: N1-acyl analogues can convert to LSD during gas chromatography-mass spectrometry (a laboratory identification technique), so results depend on method (Zhang et al., 2023; Tanaka et al., 2020); sodium fluoride prevented conversion in stored biological samples (Wachełko et al., 2025).
- What to look for: Third-party mass-spectrometry results per batch, from drug-checking services such as DanceSafe or Energy Control. No reputable brand or compounding pharmacy exists for analogues.
Practical Considerations
- Time to effect: Oral effects begin within about 1–2 hours and last 8–12 hours (Dolder et al., 2017); the main anxiety endpoint was measured at 4 weeks (Robison et al., 2025).
- Common pitfalls: Assuming analogues match LSD doses: 1P-LSD had about 38% of LSD’s potency in a mouse test (Brandt et al., 2016), and survey users rated analogues weaker (Coney et al., 2017). Unverified product identity compounds this.
- Regulatory status: LSD is Schedule I (the most restrictive US category). 1P-LSD is reportedly unscheduled but may be treated as an LSD analogue under the Federal Analogue Act if intended for human consumption; many European countries reportedly control it.
- Cost and accessibility: Research-chemical vendors are the only source, with no reimbursement and legal risk. The LSD developer, Definium Therapeutics, reports it is advancing toward a new drug application (a formal request for approval) (sponsor press release).
- Payer incentives: No analysis of payer incentives for analogues was found; none is reimbursed, so any structural payer bias concerns an approved LSD product versus low-cost antidepressants and is undocumented.
- Drug testing: Standard urine screens did not detect analogues or their metabolites in rats after recreational-range doses (Wagmann et al., 2019).
Interaction with Foundational Habits
- Sleep: Direction: indirect. Effects last 8–12 hours and can extend into the night, while repeated 10 µg LSD lengthened next-night sleep by 24.3 minutes (Allen et al., 2024). Practical consideration: morning timing keeps the effect window clear of bedtime.
- Nutrition: Direction: none. No diet-analogue studies exist; a Basel trial requires abstaining from caffeine-type drinks on session days (NCT07309471). Practical consideration: caffeine adds to heart-rate and anxiety effects.
- Exercise: Direction: none. LSD raises heart rate above 100 beats per minute in up to 25% of participants (Holze et al., 2022), so strenuous exertion during the effect window adds cardiovascular load. No exercise trials exist.
- Stress management: Direction: potentiating. Positive acute subjective effects correlated with long-term anxiety reductions after LSD (Holze et al., 2023), so calm setting and supportive preparation are treated as relevant; no analogue data exist.
Monitoring Protocol & Defining Success
Baseline assessment before any exposure would cover cardiovascular status, liver enzymes, psychiatric history, current medications and product identity, because uncontrolled hypertension, psychotic or bipolar family history and interacting medications exclude participants from a Basel trial (NCT07309471). Results are recorded as a personal reference for later comparison, since no analogue-specific targets exist.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Resting blood pressure | Below 120/80 mmHg | Acute rises follow LSD-type exposure | Conventional hypertension thresholds are 130/80 or 140/90 mmHg by guideline; a Basel trial excludes above 140/90. Measure seated after five minutes’ rest |
| Resting heart rate | 50–70 beats per minute | Heart rate exceeded 100 in up to 25% after LSD | Conventional range 60–100. Measure in the morning before caffeine |
| Corrected QT interval on electrocardiogram | Below 430 ms | Fatal arrhythmia reported with AL-LAD | QTc is the QT interval corrected for heart rate (electrical recovery time). Conventional limits 450 ms (men) and 460 ms (women) |
| Echocardiogram (heart ultrasound) | No more than trivial valve leakage; no valve thickening | 5-HT2B activation can scar valves with repeated exposure | Baseline before repeated use; proposed for long-term microdosing studies. No analogue-specific protocol exists |
| Alanine and aspartate aminotransferases (liver enzymes) | Each below 25 U/L | Organ toxicity of analogues is unstudied | ALT (alanine aminotransferase) and AST (aspartate aminotransferase) rise with liver injury. Conventional upper limit about 40 U/L. Fasting not required. LSD trials showed unchanged liver function |
| Anxiety and depression questionnaires | No established target for analogues; track change from own baseline (minimal symptoms are scores of 0–4) | Detects emotional worsening or improvement | GAD-7 (Generalized Anxiety Disorder 7-item scale) and PHQ-9 (Patient Health Questionnaire-9) are common examples |
| Batch identity test (laboratory mass spectrometry) | One labelled compound; no unlisted lysergamides or impurities | Products are often misidentified | Mass spectrometry identifies compounds by molecular mass. Colour reagents flag only an indole, and N1-acyl analogues can convert to LSD during some methods |
Ongoing monitoring would cover blood pressure and heart rate at baseline, hourly through the effect window and at resolution on each exposure day; questionnaires at 1 week, 4 weeks and 12 weeks; then electrocardiogram and liver enzymes every 6–12 months, with echocardiography added for repeated low-dose use, as proposed by Rouaud et al., 2024. Qualitative markers include:
- Sleep quality and duration
- Energy and mood stability
- Cognitive clarity
- Unusual perceptions or intrusive visual changes after exposure
Emerging Research
For health- and longevity-oriented adults, the research most relevant to analogues is summarised below.
- First-in-human analogue pharmacokinetics: A Basel randomised crossover trial (each participant receives every treatment in turn) compares DDH-LSD, a novel LSD analogue expected to act for a shorter time, with LSD and placebo in 24 volunteers; primary endpoints are effective dose and half-life (NCT07309471).
- Phase 3 LSD programme (parent compound): Definium Therapeutics runs phase 3 (large confirmatory) trials: Voyage (NCT06741228; 214 participants) and Panorama (NCT06809595; 245) in generalized anxiety, primary endpoint HAM-A at week 12, and Emerge (NCT06941844; 149) in major depression; sponsor-reported positive topline results (Voyage press release, Panorama press release) are not peer reviewed.
- Cluster headache: A Radboud phase 2 (mid-stage efficacy) trial tests LSD in 65 people with chronic cluster headache; the primary endpoint is change in weekly attack frequency, with completion expected April 2027 (NCT05477459).
- Longevity signals versus scepticism: LSD extended Caenorhabditis elegans lifespan in a preprint (Carrilho et al., 2025), but a mortality comparison found psychedelic personalities did not outlive cancer or aging researchers (Lerer, 2026).
- Non-hallucinogenic scaffolds: Simplified ergolines with reduced heart-damage potential were reported (Basargin et al., 2026), while reviewers doubt claims of non-hallucinogenicity resting on animal data (Kehler & Lindskov, 2025).
- Safety and regulation gaps: Valve risk with chronic microdosing is untested (Tagen et al., 2023); human metabolism of N1-substituted lysergamides may vary between individuals (Berquist et al., 2026); abuse-potential frameworks for novel psychedelics have only been proposed (Heal et al., 2026).
Conclusion
LSD analogues are close chemical relatives of LSD, sold as research chemicals, with no approved medical use. For health- and longevity-oriented adults, the evidence base is thin and largely borrowed: the best human data concern LSD itself, and only indirect reasoning connects those results to analogues, some of which are converted into LSD in the body while others act on their own. Any benefit for anxiety, mood, or pain therefore rests on low-certainty evidence, and claims about longevity rest on early laboratory work in worms and, for a related compound, mice. The main risks are intense, hours-long altered states, rises in heart rate and blood pressure, and rare severe reactions described in single cases; uncertain product identity and dose, heart-valve damage and organ toxicity are rated speculative because they rest on laboratory analyses or inference rather than studies in people. Much of the supporting evidence comes from companies developing LSD-related products or sponsoring LSD trials (such as Definium Therapeutics, Eleusis, BetterLife Pharma and Synex Synthetics), parties with a financial stake, and independent replication is limited. Legal status differs by country and adds practical uncertainty. Overall, analogues are an unverified variation on a compound that is itself still being tested, and their effects, purity, and long-term safety remain largely unmeasured.